Evidence method
Level · gp.fundamentals.debt_to_revenue
42.78% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
WST · Sep 30, 2019
WEST PHARMACEUTICAL SERVICES INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000105770-19-000045General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
6.95% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
23.70% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.shares_outstanding
-0.12% · CORE · VALID
Evidence method
Yoy · gp.fundamentals.revenue
5.65% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
50.52% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
32.41% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
14.76% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
2.04% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
1.18% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History39 statesSelf-history eligible
Mar 31, 201910/10 normalizedLevel 3Jun 30, 201910/10 normalizedLevel 3Sep 30, 201910/10 normalizedLevel 3Dec 31, 20198/8 normalizedLevel 3Mar 31, 20209/9 normalizedLevel 3Jun 30, 20209/9 normalizedLevel 3Sep 30, 20209/9 normalizedLevel 3Dec 31, 20209/9 normalizedLevel 3Mar 31, 20219/9 normalizedLevel 3Jun 30, 20219/9 normalizedLevel 3Sep 30, 20219/9 normalizedLevel 3Dec 31, 20219/9 normalizedLevel 3Mar 31, 20229/9 normalizedLevel 3Jun 30, 20229/9 normalizedLevel 3Sep 30, 20229/9 normalizedLevel 3Dec 31, 20229/9 normalizedLevel 3Mar 31, 20239/9 normalizedLevel 3Jun 30, 20239/9 normalizedLevel 3Sep 30, 20239/9 normalizedLevel 3Sep 30, 20269/9 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 41.73%
- Current
- 42.78%
- Delta
- 1.05%
- Previous
- 6.03%
- Current
- 6.95%
- Delta
- 0.93%
- Previous
- 22.38%
- Current
- 23.70%
- Delta
- 1.32%
- Previous
- 0.29%
- Current
- -0.12%
- Delta
- -0.41%
- Previous
- 4.96%
- Current
- 5.65%
- Delta
- 0.69%
- Previous
- 49.46%
- Current
- 50.52%
- Delta
- 1.06%
- Previous
- 33.62%
- Current
- 32.41%
- Delta
- -1.21%
- Previous
- 17.14%
- Current
- 14.76%
- Delta
- -2.38%
- Previous
- 2.04%
- Current
- 2.04%
- Delta
- -0.00%
- Previous
- 1.53%
- Current
- 1.18%
- Delta
- -0.35%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · WST Fundamental State →Has State · WEST PHARMACEUTICAL SERVICES INC →Transitioned To · WST Fundamental State →Transitioned To · WST BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · WST CAPEX_INTENSITY_INCREASED →Transitioned To · WST CASH_GENERATION_INCREASED →Transitioned To · WST R_AND_D_INTENSITY_DECREASED →Transitioned To · WST SBC_INTENSITY_DECREASED →Transitioned To · WST DILUTION_DECREASED →Transitioned To · WST GROWTH_INCREASED →Transitioned To · WST INVENTORY_PRESSURE_INCREASED →Transitioned To · WST MARGIN_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.